New insider activity at Tango Therapeutics ( (TNGX) ) has taken place on October 27, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Significant shareholder Third Rock Ventures IV, L.P. has recently sold 477,401 shares of Tango Therapeutics stock, amounting to a total transaction value of $4,845,620.
Recent Updates on TNGX stock
In the last 24 hours, Tango Therapeutics has been in the spotlight due to updates on multiple ongoing clinical studies and a subsequent adjustment in its stock price target by Guggenheim analyst Michael Schmidt. Tango Therapeutics is involved in several Phase 1/2 clinical trials focusing on advanced or metastatic solid tumors with specific genetic mutations, such as MTAP deletion and STK11 mutation. These studies aim to evaluate the safety, tolerability, and efficacy of various drug combinations, including MAT2A and PRMT5 inhibitors, as well as CoREST inhibitors combined with anti-PD-1 antibodies. The progress in these trials is crucial as they target patient groups with limited treatment options, potentially positioning Tango favorably in the oncology sector. Following the disclosure of promising Phase 1/2 data for vopimetostat in solid tumor patients, Guggenheim raised its price target for Tango Therapeutics, reflecting increased confidence in the company’s clinical advancements and potential market impact.
Spark’s Take on TNGX Stock
According to Spark, TipRanks’ AI Analyst, TNGX is a Neutral.
Tango Therapeutics’ overall stock score is primarily impacted by its financial performance, which is challenged by declining revenues and persistent losses. Technical analysis provides a mixed outlook with some positive momentum indicators, but valuation remains unattractive due to negative earnings and lack of dividends. The absence of earnings call insights and corporate events limits additional context.
To see Spark’s full report on TNGX stock, click here.
More about Tango Therapeutics
YTD Price Performance: 139.46%
Average Trading Volume: 2,630,651
Technical Sentiment Signal: Buy
Current Market Cap: $833.9M